Ian Estepan | Senior Vice President, Chief of Staff and Corporate Affairs |
Douglas Ingram | President and Chief Executive Officer |
Sandy Mahatme | Executive Vice President, Chief Financial Officer and Chief Business Officer |
Bo Cumbo | Executive Vice President and Chief Commercial Officer |
Louise Rodino-Klapac | Senior Vice President, Gene Therapy |
Gilmore O'Neill | Executive Vice President, R&D and Chief Medical Officer |
Alethia Young | Cantor Fitzgerald |
Whitney Ijem | Guggenheim |
Christopher Marai | Nomura |
Brian Abrahams | RBC Capital Markets |
Debjit Chattopadhyay | H.C. Wainwright |
Tazeen Ahmad | Bank of America Merrill Lynch |
Gena Wang | Barclays |
Salveen Richter | Goldman Sachs |
Danielle Brill | Piper Jaffray |
Joel Beatty | Citi |
Ritu Baral | Cowen |
Brian Skorney | Robert W. Baird |
Liisa Bayko | JMP Securities |
Yun Zhong | Janney |
Tim Chiang | BTIG |
Good day, ladies and gentlemen and welcome to the Sarepta Therapeutics Third Quarter 2019 Earnings Call. [Operator Instructions] After the speakers' presentation, there will be a question-and-answer session [Operator Instructions]
And now, I'd like to introduce your host for today's program, Ian Estepan, Senior Vice President, Chief of Staff and Corporate Affairs. Please go ahead.
Thank you, Michelle, and thank you all for joining today's call.